TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03534713
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40mg/m² given once a week during 5 weeks
Study: NCT00499460
Drug: oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single administration of three 5-mg oxycodone tablets or a 15-mg dose
Study: NCT03190967
Drug: T-DM1
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T-DM1 3.6 mg/kg intravenous (IV) every 21 days
Study: NCT03190967
Drug: TMZ
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase I: TMZ 30, 40 or 50 mg/m\^2 daily Phase II: TMZ at recommended phase 2 dose (RP2D) estimated in Phase I dose escalation part of the study.
Study: NCT02678104
Drug: Intra-alveolar application of Manuka Honey
Normalized name: manuka oil
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-alveolar application of Manuka Honey directly after extraction.
Study: NCT03021590
Drug: Levofloxacin 500Mg Oral Tablet
Normalized name: Levofloxacin 500mg Oral tablet
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 1000 mg Tablets , Esomeprazole 20 mg Capsule,Levofloxacin 500 mg Tablets and Tinidazole 500 mg Tablets all every 12 hours for 14 days all by mouth
Study: NCT02438761
Drug: PF-05212384
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections~The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression.
Study: NCT04673461
Drug: STA363 containing 90 mg (60 mg/mL) lactic acid
Normalized name: lactic acid 60 MG/ML
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: STA363 (90 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
Study: NCT04673461
Drug: STA363 containing 180 mg (120 mg/mL) lactic acid
Normalized name: lactic acid 120 MG/ML
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: STA363 (180 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
Study: NCT04107805
Drug: BI 1323495
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04107805
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration
Study: NCT00025454
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01852604
Drug: Samatasvir
Normalized name: Samatasvir
DrugBank: Samatasvir (DB12660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.
Study: NCT01852604
Drug: Simeprevir
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simeprevir will be supplied as 75 and 150 mg oral capsules.
Study: NCT01852604
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.
Study: NCT01852604
Drug: Ritonavir (RTV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir will be supplied as 80 mg/mL oral solution.
Study: NCT02802930
Drug: Sodium chloride [NaCl]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
Study: NCT01378845
Drug: Tracleer
Normalized name: Tracleer
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o
Study: NCT01378845
Drug: Prostavasin
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostavasin 60 µg i.v, 5 days per week for 2 weeks
Study: NCT00090766
Drug: valganciclovir [Valcyte]
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: po daily (dose based on body surface area and CrCL)
Study: NCT02941926
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ribociclib was centrally supplied to the investigators and administered orally once a day on days 1-21 of each 28 day cycle at a starting dose of 600 mg daily
Study: NCT02941926
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole was procured locally and administered orally once a day on a continuous daily schedule at a dose of 2.5 mg
Study: NCT02941926
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin was procured locally and administered in men and premenopausal women as an injectable subcutaneous implant administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 3.6 mg (cycle = 28 days)
Study: NCT02941926
Drug: Leuprolide
Normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide was procured locally and administered in men and premenopausal women as an injectable intramuscular depot administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 7.5 mg (cycle= 28 days)
Study: NCT02910765
Drug: methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02910765
Drug: ozone
Normalized name: OZONE
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03661125
Drug: Saracatinib
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.
Study: NCT00526396
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg/m2 on day 1 for 6 cycles
Study: NCT00526396
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2 on days 1,2,3 for 6 cycles
Study: NCT00526396
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin on day 1 for 6 cycles, starting dose 80 mg/m2, toxicity adjusted after first cycle
Study: NCT00526396
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: etoposide on days 1,2,3 for 6 cycles, starting dose 100 mg/m2, toxicity adjusted dosing after first cycle
Study: NCT00972777
Drug: Besifloxacin
Normalized name: Besifloxacin
DrugBank: Besifloxacin (DB06771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Besifloxacin 0.6% administered into the study eye two times a day for three days.
Study: NCT00972777
Drug: Vehicle (Placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle administered to the study eye two times a day for three days.
Study: NCT00080496
Drug: Imipenem
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00080496
Drug: Cilastatin
Normalized name: Cilastatin
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00014586
Drug: bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00014586
Drug: goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003000
Drug: morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01531361
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01531361
Drug: Sorafenib Tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01531361
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00965549
Drug: INSULIN GLARGINE (HOE901)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
Study: NCT00965549
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)
Study: NCT00965549
Drug: Insulin Glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
Study: NCT00023725
Drug: semaxanib
Normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00741104
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment of RA with Infliximab according to and under normal routine clinical practice.
Study: NCT01786434
Drug: Routine medication arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 micrograms of fentanyl given before the procedure
Study: NCT00455754
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02180568
Drug: Lipiodol
Normalized name: Lipiodol
DrugBank: Ethiodized oil (DB00965)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00093158
Drug: Angiomax (bivalirudin) anticoagulant
Normalized name: bivalirudin Injection [Angiomax]
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02050828
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02652546
Drug: Assess Safety
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
Study: NCT02652546
Drug: Effect of drug on T-cell count
Normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points
Study: NCT04348136
Drug: JR-141
Normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN TRANSFERRIN RECEPTOR) (HUMAN-MUS MUSCULUS MONOCLONAL JR-141 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 2-AMINO ACID LINKER) FUSION PROTEIN WITH HUMAN IDURONATE-2-SULFATASE, DISULFIDE WITH HUMAN-MUS MUSCULUS MONO
DrugBank: Pabinafusp alfa (DB15633)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: IV infusion, 2.0 mg/kg/week
Study: NCT01690988
Drug: Ketamine (0.5 mg/kg)
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
Study: NCT01690988
Drug: Normal Saline (placebo)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline IV following induction of anesthesia or administration of sedative medications
Study: NCT01690988
Drug: Ketamine (1 mg/kg)
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
Study: NCT00075621
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection
Study: NCT00075621
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/kg over 2 days
Study: NCT03513276
Drug: 100cc of 2% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal analgesia + Local infiltration anesthesia
Study: NCT03513276
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal analgesia + Saline solution
Study: NCT00012207
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00012207
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005792
Drug: etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide phosphate 1363 mg/m\^2/day IV over 4 hours (total dose 2726 mg/m\^2, or 2400 mg/m\^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3
Study: NCT00005792
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2), followed immediately by topotecan. Days -7, -6, -5
Study: NCT00005792
Drug: topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan 3.3 mg/m\^2/day (starting total dose = 10 mg/m\^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5
Study: NCT02443155
Drug: NNC0114-0006
Normalized name: NNC0114-0006
DrugBank: NNC0114-0006 (DB18361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment
Study: NCT02443155
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
Study: NCT01664182
Drug: Pazopanib Hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01664182
Drug: Sorafenib Tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01664182
Drug: Sunitinib Malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01807611
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV.
Study: NCT01807611
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV.
Study: NCT01807611
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV.
Study: NCT01807611
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
Study: NCT01807611
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously or orally.
Study: NCT00650897
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-20 mg once daily
Study: NCT00290732
Drug: Intraductal arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter
Study: NCT02144857
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg
Study: NCT02144857
Drug: ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 45 mg
Study: NCT02144857
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 2.5-3 mg/kgr
Study: NCT02144857
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg
Study: NCT02144857
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30mg
Study: NCT01625611
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone 100 mg titrated over one week
Study: NCT03531086
Drug: Ioflupane I 123
Normalized name: ioflupane I 123
DrugBank: Ioflupane I-123 (DB08824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ioflupane I 123 will be administered IV push prior to SPECT imaging
Study: NCT02870153
Drug: SOX
Normalized name: Vasoxyl
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
Study: NCT00290732
Drug: Intravenous arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.
Study: NCT00964366
Drug: clindamycin and benzoyl peroxide
Normalized name: clindamycin and benzoyl peroxide KIT
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
Study: NCT00964366
Drug: Dapsone gel
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily applications of dapsone gel
Study: NCT01060722
Drug: MOD-4023 (long lasting hGH)
Normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Single subcutaneous dose of MOD-4023
Study: NCT00851942
Drug: Synacthen (Tetracosactrin)
Normalized name: Synacthen Depot
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV injection of 250 micrograms of Synacthen in 1ml
Study: NCT00096434
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00130637
Drug: Daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03537651
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet for oral administration.
Study: NCT00822913
Drug: Intravesical injection of Botulinum A toxin
Normalized name: botulinum toxin type A Injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: One treatment, 200 U vials diluted in 20 ml normal saline
Study: NCT02967237
Drug: insulin glargine (U300)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT02221674
Drug: Tapentadol
Normalized name: Tapentadol
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04354662
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg d1
Study: NCT04354662
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m2, d1;
Study: NCT04354662
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m², d1
Study: NCT04459078
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of (200mg/3weeks)
Study: NCT04459078
Drug: Albumin Paclitacxel
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles)
Study: NCT04459078
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given oral of Apatinib (250mg Qd po for 5 days, take rest for 2 days every week)
Study: NCT03385226
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells.
Study: NCT01558947
Drug: Peri-operative chemotherapy of ECX
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4\~6 weeks after surgery.